CCG Wealth Management LLC Acquires Shares of 150,000 Structure Therapeutics Inc. (NASDAQ:GPCR)

CCG Wealth Management LLC purchased a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,000 shares of the company's stock, valued at approximately $4,068,000. Structure Therapeutics makes up about 2.3% of CCG Wealth Management LLC's holdings, making the stock its 10th biggest position. CCG Wealth Management LLC owned approximately 0.26% of Structure Therapeutics at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Structure Therapeutics in the fourth quarter worth approximately $40,000. Assetmark Inc. raised its stake in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC bought a new stake in Structure Therapeutics during the third quarter valued at approximately $202,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

NASDAQ GPCR traded down $0.68 during trading on Thursday, hitting $30.02. 969,565 shares of the company's stock traded hands, compared to its average volume of 793,619. The firm has a market cap of $1.72 billion, a P/E ratio of -40.57 and a beta of -2.76. The stock has a fifty day moving average of $29.40 and a two-hundred day moving average of $35.03. Structure Therapeutics Inc. has a 12-month low of $23.50 and a 12-month high of $62.74.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities restated a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and an average price target of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.